AU2003267361A1 - Orthopoxvirus antigens and use thereof - Google Patents

Orthopoxvirus antigens and use thereof

Info

Publication number
AU2003267361A1
AU2003267361A1 AU2003267361A AU2003267361A AU2003267361A1 AU 2003267361 A1 AU2003267361 A1 AU 2003267361A1 AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A AU2003267361 A AU 2003267361A AU 2003267361 A1 AU2003267361 A1 AU 2003267361A1
Authority
AU
Australia
Prior art keywords
orthopoxvirus
antigens
orthopoxvirus antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267361A
Other versions
AU2003267361A8 (en
Inventor
Ingo Drexler
Volker Erfle
Caroline Staib
Gerd Sutter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10242318A external-priority patent/DE10242318A1/en
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of AU2003267361A8 publication Critical patent/AU2003267361A8/en
Publication of AU2003267361A1 publication Critical patent/AU2003267361A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus
AU2003267361A 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof Abandoned AU2003267361A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10242318.0 2002-09-12
DE10242318A DE10242318A1 (en) 2002-09-12 2002-09-12 Orthopox virus antigens and their use
EP02022252.7 2002-10-02
EP20020022252 EP1398380A1 (en) 2002-09-12 2002-10-02 Orthopoxvirus antigens and use thereof
PCT/EP2003/010226 WO2004024756A2 (en) 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof

Publications (2)

Publication Number Publication Date
AU2003267361A8 AU2003267361A8 (en) 2004-04-30
AU2003267361A1 true AU2003267361A1 (en) 2004-04-30

Family

ID=31995061

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267361A Abandoned AU2003267361A1 (en) 2002-09-12 2003-09-12 Orthopoxvirus antigens and use thereof

Country Status (2)

Country Link
AU (1) AU2003267361A1 (en)
WO (1) WO2004024756A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217526B2 (en) 2003-01-24 2007-05-15 University Of Massachusetts Medical School Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
ITRM20030386A1 (en) * 2003-08-05 2005-02-06 Istituto Naz Per Le Malattie Infettive Lazz METHOD AND DIAGNOSTIC TESTS BASED ON THE CITOFLUORIMETRIC ANALYSIS OF ANTIGEN-SPECIFIC T LYMPHOCYTES.
JP2018510143A (en) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター Use of inactivated non-replicating modified vaccinia virus Ankara (MVA) in monotherapy for solid tumors or in combination with immune checkpoint blockers
JP6936153B2 (en) 2015-04-17 2021-09-15 メモリアル スローン ケタリング キャンサー センター Use of MVA or MVAΔE3L as a solid tumor immunotherapeutic agent
JP7034080B2 (en) 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター Recombinant MVA or MVAΔE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
KR20180133395A (en) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 Replicable attenuated vaccinia virus with or without the expression of human FLT3L or GM-CSF and for which the thymidine kinase has been deleted for cancer immunotherapy
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN117756949A (en) * 2024-02-21 2024-03-26 中国人民解放军军事科学院军事医学研究院 Orthopoxvirus fusion antigen and application thereof

Also Published As

Publication number Publication date
AU2003267361A8 (en) 2004-04-30
WO2004024756A2 (en) 2004-03-25
WO2004024756A3 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
AU2003299778A1 (en) Antibodies against gpr64 and uses thereof
AU2002357643A1 (en) The human mob-5 (il-24) receptors and uses thereof
AU2003272187A1 (en) Novel nanoparticles and use thereof
AU2002315389A1 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
AU2002314433A1 (en) Ephrin-tie receptor materials and methods
AU2003241477A1 (en) Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2002315388A1 (en) Novel phenylamino-pyrimidines and uses thereof
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003224313A1 (en) Mycobacterial antigens and uses thereof
AU2002343724A1 (en) Adhesive and use thereof
AU2003298129A1 (en) Floor-furnace chimney and the use thereof
AU2003219093A1 (en) Anti-hpv-16 e7 antibodies and their use
AU2003267361A1 (en) Orthopoxvirus antigens and use thereof
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003207628A1 (en) Structural and cytoskeleton-associated proteins
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003263329A1 (en) Foxp2 and uses thereof
AU2003292774A1 (en) Novel proteins and use thereof
AU2003280992A1 (en) Novel proteins and use thereof
AU2003216442A1 (en) Enkurin and uses thereof
AU2003263326A1 (en) Foxp1 and uses thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase